These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2694718)

  • 1. [Flow cytometric analysis of T lymphocyte subsets after human bone marrow transplantation using monoclonal antibodies and dual immunofluorescence].
    Matsue K; Yasue S; Iwabuchi K; Ohtsuka M; Ueda M; Kondo K; Shiobara S; Mori T; Matsuda T; Harada M
    Nihon Ketsueki Gakkai Zasshi; 1989 May; 52(3):659-64. PubMed ID: 2694718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased numbers of CD8+CD11+, CD8+CD11- and CD8+Leu7+ cells in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Yabe H; Yabe M; Kato S; Kimura M; Iwaki K
    Bone Marrow Transplant; 1990 May; 5(5):295-300. PubMed ID: 1693537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
    Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
    Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked increase of CD8+S6F1+ and CD8+CD57+ cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation.
    Fukuda H; Nakamura H; Tominaga N; Teshima H; Hiraoka A; Shibata H; Masaoka T
    Bone Marrow Transplant; 1994 Feb; 13(2):181-5. PubMed ID: 7515741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked increase of CD57+CD16- cells in long-term survivors of graft-versus-host disease after allogeneic bone marrow transplantation.
    Fukuda H; Nakamura H; Tominaga N; Teshima H; Hiraoka A; Shibata H; Masaoka T
    Jpn J Clin Oncol; 1992 Aug; 22(4):238-43. PubMed ID: 1359173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell subpopulations defined by monoclonal antibodies after HLA-identical sibling marrow transplantation. II. Activated and functional subsets of helper-inducer and cytotoxic-suppressor subpopulations defined by two-colour fluorescence flow cytometry.
    Atkinson K
    Bone Marrow Transplant; 1986 Dec; 1(2):121-32. PubMed ID: 2971408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features.
    D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Fusilli S; Zendoli F; Carotenuto M
    Haematologica; 1998 Mar; 83(3):197-203. PubMed ID: 9573672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation.
    Kawanishi Y; Passweg J; Drobyski WR; Rowlings P; Cook-Craig A; Casper J; Pietryga D; Garbrecht F; Camitta B; Horowitz M; Juckett M; Margolis D; Flomenberg N; Keever-Taylor CA
    Bone Marrow Transplant; 1997 Jun; 19(11):1069-77. PubMed ID: 9193748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation.
    Rojas B; Cuhna R; Zafirakis P; Ramirez JM; Lizan-garciía M; Zhao T; Foster CS
    Exp Eye Res; 2005 Sep; 81(3):313-25. PubMed ID: 16129099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
    Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regeneration of functional and activated NK and T sub-subset cells in the marrow and blood after autologous bone marrow transplantation: a prospective phenotypic study with 2/3-color FACS analysis.
    Bengtsson M; Tötterman TH; Smedmyr B; Festin R; Oberg G; Simonsson B
    Leukemia; 1989 Jan; 3(1):68-75. PubMed ID: 2535882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
    Truitt RL; Atasoylu AA
    Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor.
    Jun HX; Jun CY; Yu ZX
    Haematologica; 2004 Dec; 89(12):1517-24. PubMed ID: 15590404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
    Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
    Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.